CompanyIKTNasdaqWilmington, DE

Inhibikase Therapeutics

Inhibikase Therapeutics develops IKT-001, a prodrug of imatinib for pulmonary arterial hypertension (PAH), an orphan indication.

SEC EDGAR ClinicalTrials.gov precedenceresearch.com

424B3Sep 25Latest SEC filing

Aug 11Latest story

August 2026

Inhibikase reports Q2 2026 results as Phase 3 PAH trial expands across 26 countries

Aug 11Quarterly updateInhibikase Therapeutics

July 2026

Inhibikase swaps RA Capital's common shares for pre-funded warrant

Jul 29FinancingInhibikase Therapeutics

FDA grants orphan drug status to Inhibikase's IKT-001 for PAH

Jul 23Regulatory milestoneIKT-001 Inhibikase Therapeutics

June 2026

Inhibikase completes annual meeting filings, board elections finalized

Jun 29PeopleInhibikase Therapeutics